Actively Recruiting

Phase 1
Phase 2
Age: 50Years +
All Genders
NCT05986864

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Led by Skyline Therapeutics (US) Inc. · Updated on 2025-01-09

68

Participants Needed

9

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.

CONDITIONS

Official Title

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary and able to sign informed consent and complete study procedures
  • Age 50 years or older at screening
  • Diagnosis of neovascular age-related macular degeneration (nAMD) in the study eye as determined by the investigator
  • Active choroidal neovascularization (CNV) lesions secondary to age-related macular degeneration
  • Responsive to anti-VEGF therapy before study treatment as assessed by the investigator
Not Eligible

You will not qualify if you...

  • Active intraocular or periocular infection or inflammation in the study eye at baseline
  • Retinal pigment epithelial tear in the study eye at screening
  • Current vitreous hemorrhage in the study eye or history of vitreous hemorrhage within 4 weeks before baseline
  • Any condition that may limit visual improvement in the study eye as judged by the investigator
  • History of retinal detachment or active retinal detachment in the study eye
  • Previous gene therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Retina Vitreous Associates of Florida - Saint Petersburg

St. Petersburg, Florida, United States, 33711

Not Yet Recruiting

2

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States, 02114

Actively Recruiting

3

Retina Consultants of Texas

Katy, Texas, United States, 77494

Actively Recruiting

4

Wagner Kapoor Research Institute

Norfolk, Virginia, United States, 23502

Actively Recruiting

5

The Second Hospital Of Anhui Medical University

Hefei, Anhui, China

Actively Recruiting

6

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Actively Recruiting

7

Eye Hospital, WMU (Zhejiang Eye Hospital)

Wenzhou, Zhejiang, China

Actively Recruiting

8

Beijing Hospital

Beijing, China

Actively Recruiting

9

Peking Union Medical College Hospital

Beijing, China

Actively Recruiting

Loading map...

Research Team

Y

Yongqin Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here